Gene-Editing Therapy Reduced Cholesterol in Trial
A single infusion of CTX310 successfully lowered lipid levels for 12 months in an early-stage clinical study.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Do you trust the safety of emerging gene-editing treatments for managing chronic health conditions?
An experimental gene-editing therapy, CTX310, demonstrated sustained reductions in LDL cholesterol and triglycerides 12 months after a single infusion in 15 patients with medication-resistant lipid disorders. These Phase 1 results were published in the NEJM on August 27, 2026.
Why it matters
By targeting the ANGPTL3 gene, which regulates blood fats associated with heart disease, this research offers a potential one-time intervention for patients who do not respond to existing lipid-lowering medications. The sustained effect over a year highlights the potential for CRISPR-based treatments to move beyond transient daily therapies.
At the highest dose of 0.8 milligrams per kilogram, CTX310 achieved a 52.5% reduction in LDL cholesterol and a 47.8% decrease in triglycerides compared to pretreatment levels. This performance was maintained for the full 12-month duration of the follow-up period.
The players
CRISPR Therapeutics AG
A biotechnology company focused on developing CRISPR-Cas9 gene-editing medicines for human diseases.
Cleveland Clinic
A prominent academic medical center that hosted the clinical trial for the experimental therapy.
The details
CTX310 functions by delivering CRISPR-Cas9—a molecular tool that acts as genetic scissors to cut and modify specific DNA sequences—to the liver to silence the ANGPTL3 gene. Patients received infusions ranging from 0.1 to 0.8 mg/kg following a pretreatment regimen of corticosteroids and antihistamines. No serious adverse events linked to the therapy were reported during the one-year study window.
Timeline
November 2025: Initial clinical trial data was presented.
August 27, 2026: Study results were published in the NEJM.
Next 15 years: Participants will undergo long-term safety monitoring.
The Tech Race
This study advances the use of the ANGPTL3 gene regulatory pathway to manage lipids. It represents a significant progression in the race to translate gene-silencing research into durable, single-dose therapies for chronic cardiovascular conditions.
The therapy is currently in the research stage and remains limited to trial participants with medication-resistant lipid disorders. Clinical adoption will depend on the results of larger future studies and subsequent long-term safety data scheduled to be gathered over the next 15 years.
The takeaway
This study indicates that gene editing can effectively modulate cholesterol levels for at least a year with a single infusion. Observers should track the upcoming larger clinical trials to see if these lipid-lowering results hold across diverse patient populations.
Further reading
For broader trends in genetic medicine, visit our Biotech section.
Live Poll
Do you trust the safety of emerging gene-editing treatments for managing chronic health conditions?
